Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, December 1998, p. 3276-3278, Vol. 42, No. 12
Division of Microbiology,
Received 15 June 1998/Returned for modification 13 July
1998/Accepted 9 September 1998
Quinolone resistance in clinical isolates of Campylobacter
jejuni in Sweden increased more than 20-fold at the beginning of the 1990s. Resistance to 125 µg of ciprofloxacin per ml in clinical isolates was associated with chromosomal mutations in C. jejuni leading to a Thr-86-Ile substitution in the
gyrA product and a Arg-139-Gln substitution in the
parC product.
Quinolones have been used
extensively for the treatment of diarrhea caused by Campylobacter
jejuni. Quinolones are also frequently used as prophylaxis for
travellers. The frequency of resistance to quinolones among C. jejuni strains was low (1 to 2%) in Sweden until the beginning of
the 1990s (16), when it rapidly increased to almost 25%
within a few years (17, 23). The mechanisms for quinolone
resistance in pathogenic bacteria have been shown to involve
chromosomal mutations that modify DNA gyrase (18, 20, 22,
24) or DNA topoisomerase IV (1, 21), the targets of
quinolone action. Decreased outer membrane permeability (2, 5,
13) and export through an active efflux system (3, 8)
have also been linked to quinolone resistance. Recently, transferable
plasmid-borne resistance to quinolones has also been inferred
(10). In this study, we investigated mutations of gyrase and
topoisomerase IV genes in C. jejuni.
Campylobacter strains were grown at 37°C in a microaerobic
atmosphere (5% O2, 10% CO2, 85%
N2) for 48 h on blood-free, nonselective nutrient agar
(Oxoid Ltd., Basingstoke, United Kingdom). Determination of MICs by
broth dilution was performed as described previously (16).
Characteristics of the clinical isolates studied are summarized in
Table 1. A quinolone-susceptible
reference strain (8382), originally isolated from a fecal sample and
susceptible to tetracyclines, erythromycin, and clindamycin, was also
included.
In order to characterize mutations associated with resistance, the
quinolone resistance-determining region (QRDR) of the gyrA gene in the clinical isolates was amplified by PCR. The primers and the
method were described previously (22). The templates for PCR
amplification were prepared by the boiling method (19). Products of PCR were purified as described previously (11)
and digested with EcoRI and BamHI, generating a
fragment of 219 bp, which was cloned into M13mp18 or M13mp19 as
described previously (14).
The QRDR sequence of the gyrA gene obtained for the eight
isolates in Table 1 is shown in Fig. 1A.
The sequence for the quinolone-susceptible strains 8382 and 34156 (with
one exception; see below) was identical to that previously reported
(22). The QRDRs of the quinolone-resistant isolates (Table
1) all showed the C-to-T transition at nucleotide 256 (Fig. 1A),
leading to a Thr-86-Ile substitution, which was earlier observed to
mediate high quinolone resistance (22). All eight isolates
also had a silent C-to-T change at nucleotide 242 (Fig. 1A) which was
not previously reported.
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Rapid Emergence of High-Level Resistance to
Quinolones in Campylobacter jejuni Associated with
Mutational Changes in gyrA and parC
ABSTRACT
Top
Abstract
Text
References
TEXT
Top
Abstract
Text
References
TABLE 1.
Antibiotic resistance in clinical isolates of
C. jejuni
View larger version (44K):
[in a new window]
FIG. 1.
Nucleotide and deduced amino acid sequences of the QRDR
of the gyrA gene (A) and the corresponding region of the
parC gene (B) of the quinolone-resistant isolates (Table 1).
The primers for PCR amplification in each case are indicated. (A) The
Thr-86-Ile substitution, associated with high-level resistance to
quinolones, is shown. (B) Numbering refers to the amino acid residues.
Differences in amino acids in comparison to the product of the
corresponding gene of E. coli are shown.
In order to identify further mutations associated with resistance, the QRDR of the parC gene of C. jejuni, corresponding to nucleotides 140 to 534 in Escherichia coli parC (6, 21), was amplified. Two primers were used, 5'-TGGGATCCAAACCTGTTCAGCGCCGCATT-3' (P1) and 5'-CGGAATTCGTGGTGCCGTTAAGCAAA-3' (P2). BamHI and EcoRI sites were added to the 5' ends of P1 and P2, respectively. The PCR amplification was as described previously (20), except that 1.0 mM MgCl2 and an annealing temperature of 58°C were used.
The sequence of the parC gene of C. jejuni downstream of the QRDR (sequence between positions 538 and 1238 [Fig. 2]) was determined for the quinolone-susceptible isolates (8382 and 34156 [Table 1]) and for one resistant strain (33324 [Table 1]) by three sequential runs of the capture PCR (CPCR) technique, as described previously (7). Controls without templates were included.
|
The first run of CPCR was carried out with a biotinylated primer based on the known sequence of the QRDR of C. jejuni parC (positions 412 to 437; in Fig. 2, positions 140 to 538 correspond to the QRDR). An amplified fragment of about 355 bp was obtained. The identity of the amplified DNA was confirmed by carrying out two independent PCR runs with two specific primers located downstream of the biotinylated one (nucleotides 438 to 457 and 492 to 514 [Fig. 2]). Three independent clones of the amplified DNA were sequenced as described previously (15). Based on the sequence detected by the first CPCR run (nucleotides 538 to 890 [Fig. 2]), two other CPCR runs were carried out one after the other with two biotinylated primers representing positions 807 to 835 and positions 1094 to 1116 (Fig. 2).
The amplified QRDR of C. jejuni parC was found to be slightly larger (398 bp) than that observed by Vila et al. for E. coli (395 bp) (21). The two identical sequences of this amplification product from the two quinolone-susceptible strains (8382 and 34156 in Table 1) are shown in Fig. 1B. The amino acid sequence is identical to that of the corresponding fragment in E. coli, with four exceptions. The most conspicuous of these are the two arginine residues substituted for glycine and alanine at residues 107 and 108, respectively, immediately followed by the insertion of an extra serine (Fig. 2) flanked by a sequence corresponding to a 5-bp direct repeat (CGATC). The fourth exception is an arginine instead of a glutamine at residue 139. The resistant strains all show a mutation substituting glutamine for arginine at this position. The differences at residues 107 to 109 could be endogenous to C. jejuni. An alternative interpretation could be that because of the intensive exposure to quinolones used in medicine and agriculture, C. jejuni has adapted by mutations at residues 107 to 109, resulting in a protein with a lower affinity for quinolones (resistance) but a lower enzymatic efficiency. The Gln-139-Arg substitution detected in the susceptible isolates could be regarded as a compensatory mutation resulting in an increase in enzyme activity with a concomitant loss of resistance (4).
The nucleotide sequence of the part of C. jejuni parC analyzed here (about 50% of the whole parC gene, compared to the size of the corresponding gene in E. coli) showed 94% similarity (93% after translation) to the corresponding gene in E. coli. A higher degree of similarity was found near the part of the gene corresponding to the N terminus, while the part corresponding to the C terminus was generally found to be more variable (Fig. 2).
In this study, quinolone-resistant isolates of C. jejuni, representing the increase in resistance frequency mentioned above, were analyzed for mutational changes in both the gyrA and parC genes. A single mutation in gyrA, leading to a Thr-86-Ile substitution, in combination with a single mutation in parC, leading to an Arg-139-Gln substitution, had been found in clinical isolates of C. jejuni resistant to high concentrations of ciprofloxacin. The gyrA mutation seen in this study is identical to that observed earlier in C. jejuni (22), but the C. jejuni strains examined were found to display a higher resistance level to ciprofloxacin (34 to 125 µg/ml) than what was observed in the previously mentioned study (22). The interpretation that the combination of mutations in gyrA and parC could be associated with the high resistance is supported by the data presented in Table 1, which show that isolates of the same serogroup from a patient under treatment with ciprofloxacin showed high resistance to quinolones already on the fourth day of treatment and that a comparison of susceptible isolates from the initiation of treatment with resistant isolates from the fourth day showed the two mutations. However, the gyrA and parC mutations observed did not explain why the MICs of ciprofloxacin were 34 µg/ml for strain 33325, 64 µg/ml for strain 33324, and 125 µg/ml for others (27611 and 34157). One possibility could be that there was an additional mutation(s) in another location(s) of the gyrA or gyrB gene. Mutations that affect drug permeation and efflux could also alter the ultimate MICs for these isolates.
Nucleotide sequence accession number. The sequence of the parC gene has been deposited in the EMBL database under accession number Y18300.
| |
ACKNOWLEDGMENTS |
|---|
We thank Maria Lagerström-Fermér for generously providing the information about the CPCR technique and her kind assistance in determining the parC sequence. The competent assistance of Elsy Johnson is gratefully acknowledged.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Division of Microbiology, Department of Pharmaceutical Biosciences, P.O. Box 581, Biomedical Center, Uppsala University, S-751 23 Uppsala, Sweden. Phone: 46-18-4714500. Fax: 46-18-502790. E-mail: ola.skold{at}farmbio.uu.se.
| |
REFERENCES |
|---|
|
Top
Abstract
Text
References
|
|---|
| 1. | Breines, D. M., S. Ouabdesselam, E. Y. Ng, J. Tankovic, S. Shah, C. J. Soussy, and D. C. Hooper. 1997. Quinolone resistance locus nfxD of Escherichia coli is a mutant allele of the parE gene encoding a subunit of topoisomerase IV. Antimicrob. Agents Chemother. 41:175-179[Abstract]. |
| 2. | Charvalos, E., Y. Tselentis, M. M. Hamzehpour, T. Köhler, and J.-C. Pechere. 1995. Evidence for an efflux pump in multidrug-resistant Campylobacter jejuni. Antimicrob. Agents Chemother. 39:2019-2022[Abstract]. |
| 3. |
Cohen, S. P.,
D. C. Hooper,
J. S. Wolfson,
K. S. Souza,
L. M. McMurry, and S. B. Levy.
1988.
Endogenous active efflux of norfloxacin in susceptible Escherichia coli.
Antimicrob. Agents Chemother.
32:1187-1191 |
| 4. |
Fermér, C., and G. Swedberg.
1997.
Adaptation to sulfonamide resistance in Neisseria meningitidis may have required compensatory changes to retain enzyme function: kinetic analysis of dihydropteroate synthases from N. meningitidis expressed in a knockout mutant of Escherichia coli.
J. Bacteriol.
179:831-837 |
| 5. |
Hooper, D. C.,
J. S. Wolfson,
K. S. Souza,
C. Tung,
G. L. McHugh, and M. N. Swartz.
1986.
Genetic and biochemical characterization of norfloxacin resistance in Escherichia coli.
Antimicrob. Agents Chemother.
29:639-644 |
| 6. | Kato, J., Y. Nishimura, R. Imamura, H. Niki, S. Hiraga, and H. Suzuki. 1990. New topoisomerase essential for chromosome segregation in Escherichia coli. Cell 63:393-404[Medline]. |
| 7. | Lagerström-Fermér, M., J. Parik, H. Malmgren, J. Stewart, U. Pettersson, and U. Landegren. 1991. Capture PCR: efficient amplification of DNA fragments adjacent to a known sequence in human and YAC DNA. PCR Methods Appl. 1:111-119[Medline]. |
| 8. |
Levy, S. B.
1992.
Active efflux mechanisms for antimicrobial resistance.
Antimicrob. Agents Chemother.
36:695-703 |
| 9. |
Lior, H.,
D. L. Woodward,
J. A. Edgar,
L. J. Laroche, and P. Gill.
1982.
Serotyping of Campylobacter jejuni by slide agglutination based on heat-labile antigenic factors.
J. Clin. Microbiol.
15:761-768 |
| 10. | Martinez-Martinez, L., A. Pascual, and G. A. Jacoby. 1998. Quinolone resistance from a transferable plasmid. Lancet 351:797-799[Medline]. |
| 11. | Öfverstedt, L. G., K. Hammarström, N. Balgobin, S. Hjertén, U. Pettersson, and J. Chattopadyaya. 1984. Rapid and quantitative recovery of DNA fragments from gels by displacement electrophoresis (isotachophoresis). Biochim. Biophys. Acta 782:120-126[Medline]. |
| 12. |
Penner, J. L., and J. N. Hennessy.
1980.
Passive hemagglutination technique for serotyping Campylobacter fetus subsp. jejuni on the basis of soluble heat-stable antigens.
J. Clin. Microbiol.
12:732-737 |
| 13. |
Robillard, N. J., and A. L. Scarpa.
1988.
Genetic and physiological characterization of ciprofloxacin resistance in Pseudomonas aeruginosa PAO.
Antimicrob. Agents Chemother.
32:535-539 |
| 14. | Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. |
| 15. |
Sanger, F.,
S. Nicklen, and A. R. Coulson.
1977.
DNA sequencing with chain-terminating inhibitors.
Proc. Natl. Acad. Sci. USA
74:5463-5467 |
| 16. |
Sjögren, E.,
B. Kaijser, and M. Werner.
1992.
Antimicrobial susceptibilities of Campylobacter jejuni and Campylobacter coli isolated in Sweden: a 10-year follow-up report.
Antimicrob. Agents Chemother.
36:2847-2849 |
| 17. |
Sjögren, E.,
G.-B. Lindblom, and B. Kaijser.
1997.
Norfloxacin resistance in Campylobacter jejuni and Campylobacter coli from Swedish patients.
J. Antimicrob. Chemother.
40:257-261 |
| 18. |
Stein, D. C.,
R. J. Danaher, and T. M. Cook.
1991.
Characterization of a gyrB mutation responsible for low-level nalidixic acid resistance in Neisseria gonorrhoeae.
Antimicrob. Agents Chemother.
35:622-626 |
| 19. |
Van Eys, G. J. J. M.,
C. Gravekamp,
M. J. Gerritsen,
W. Quint,
M. T. E. Cornelissen,
J. T. Schegget, and W. J. Terpstra.
1989.
Detection of leptospires in urine by polymerase chain reaction.
J. Clin. Microbiol.
27:2258-2262 |
| 20. | Vila, J., J. Ruiz, P. Goñi, A. Marcos, and T. Jimenez De Anta. 1995. Mutation in the gyrA gene of quinolone-resistant clinical isolates of Acinetobacter baumannii. Antimicrob. Agents Chemother. 39:1201-1203[Abstract]. |
| 21. | Vila, J., J. Ruiz, P. Goñi, and M. T. Jimenez De Anta. 1996. Detection of mutations in parC in quinolone-resistant clinical isolates of Escherichia coli. Antimicrob. Agents Chemother. 40:491-493[Abstract]. |
| 22. |
Wang, Y.,
W. M. Huang, and D. E. Taylor.
1993.
Cloning and nucleotide sequence of the Campylobacter jejuni gyrA gene and characterization of quinolone resistance mutations.
Antimicrob. Agents Chemother.
37:457-463 |
| 23. | Wretlind, B., A. Strömberg, L. Östlund, E. Sjögren, and B. Kaijser. 1992. Rapid emergence of quinolone resistance in Campylobacter jejuni in patients treated with norfloxacin. Scand. J. Infect. Dis. 24:685-686[Medline]. |
| 24. |
Yoshida, H.,
M. Bogaki,
M. Nakamura,
L. M. Yamanaka, and S. Nakamura.
1991.
Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli.
Antimicrob. Agents Chemother.
35:1647-1650 |
Antimicrobial Agents and Chemotherapy, December 1998, p. 3276-3278, Vol. 42, No. 12
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Vijayakumar, S., Merkx-Jacques, A., Ratnayake, D. B., Gryski, I., Obhi, R. K., Houle, S., Dozois, C. M., Creuzenet, C.
(2006). Cj1121c, a Novel UDP-4-keto-6-deoxy-GlcNAc C-4 Aminotransferase Essential for Protein Glycosylation and Virulence in Campylobacter jejuni. J. Biol. Chem.
281: 27733-27743
[Abstract] [Full Text] -
Ge, B., McDermott, P. F., White, D. G., Meng, J.
(2005). Role of Efflux Pumps and Topoisomerase Mutations in Fluoroquinolone Resistance in Campylobacter jejuni and Campylobacter coli. Antimicrob. Agents Chemother.
49: 3347-3354
[Abstract] [Full Text] -
Griggs, D. J., Johnson, M. M., Frost, J. A., Humphrey, T., Jorgensen, F., Piddock, L. J. V.
(2005). Incidence and Mechanism of Ciprofloxacin Resistance in Campylobacter spp. Isolated from Commercial Poultry Flocks in the United Kingdom before, during, and after Fluoroquinolone Treatment. Antimicrob. Agents Chemother.
49: 699-707
[Abstract] [Full Text] -
Giraud, E., Blanc, G., Bouju-Albert, A., Weill, F.-X., Donnay-Moreno, C.
(2004). Mechanisms of quinolone resistance and clonal relationship among Aeromonas salmonicida strains isolated from reared fish with furunculosis. J Med Microbiol
53: 895-901
[Abstract] [Full Text] -
Delsol, A. A., Sunderland, J., Woodward, M. J., Pumbwe, L., Piddock, L. J. V., Roe, J. M.
(2004). Emergence of fluoroquinolone resistance in the native Campylobacter coli population of pigs exposed to enrofloxacin. J Antimicrob Chemother
53: 872-874
[Abstract] [Full Text] -
Duim, B., Wagenaar, J. A., Dijkstra, J. R., Goris, J., Endtz, H. P., Vandamme, P. A. R.
(2004). Identification of Distinct Campylobacter lari Genogroups by Amplified Fragment Length Polymorphism and Protein Electrophoretic Profiles. Appl. Environ. Microbiol.
70: 18-24
[Abstract] [Full Text] -
Wilson, D. L., Bell, J. A., Young, V. B., Wilder, S. R., Mansfield, L. S., Linz, J. E.
(2003). Variation of the natural transformation frequency of Campylobacter jejuni in liquid shake culture. Microbiology
149: 3603-3615
[Abstract] [Full Text] -
Wagner, J., Jabbusch, M., Eisenblatter, M., Hahn, H., Wendt, C., Ignatius, R.
(2003). Susceptibilities of Campylobacter jejuni Isolates from Germany to Ciprofloxacin, Moxifloxacin, Erythromycin, Clindamycin, and Tetracycline. Antimicrob. Agents Chemother.
47: 2358-2361
[Abstract] [Full Text] -
Luo, N., Sahin, O., Lin, J., Michel, L. O., Zhang, Q.
(2003). In Vivo Selection of Campylobacter Isolates with High Levels of Fluoroquinolone Resistance Associated with gyrA Mutations and the Function of the CmeABC Efflux Pump. Antimicrob. Agents Chemother.
47: 390-394
[Abstract] [Full Text] -
Piddock, L. J. V., Ricci, V., Pumbwe, L., Everett, M. J., Griggs, D. J.
(2003). Fluoroquinolone resistance in Campylobacter species from man and animals: detection of mutations in topoisomerase genes. J Antimicrob Chemother
51: 19-26
[Abstract] [Full Text] -
Ge, B., Bodeis, S., Walker, R. D., White, D. G., Zhao, S., McDermott, P. F., Meng, J.
(2002). Comparison of the Etest and agar dilution for in vitro antimicrobial susceptibility testing of Campylobacter. J Antimicrob Chemother
50: 487-494
[Abstract] [Full Text] -
Morrissey, I., Salman, H., Bakker, S., Farrell, D., Bebear, C. M., Ridgway, G.
(2002). Serial passage of Chlamydia spp. in sub-inhibitory fluoroquinolone concentrations. J Antimicrob Chemother
49: 757-761
[Abstract] [Full Text] -
Wilson, D. L., Abner, S. R., Newman, T. C., Mansfield, L. S., Linz, J. E.
(2000). Identification of Ciprofloxacin-Resistant Campylobacter jejuni by Use of a Fluorogenic PCR Assay. J. Clin. Microbiol.
38: 3971-3978
[Abstract] [Full Text] -
Prats, G., Mirelis, B., Llovet, T., Muñoz, C., Miró, E., Navarro, F.
(2000). Antibiotic Resistance Trends in Enteropathogenic Bacteria Isolated in 1985-1987 and 1995-1998 in Barcelona. Antimicrob. Agents Chemother.
44: 1140-1145
[Abstract] [Full Text]
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»